{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/bacterial-vaginosis/prescribing-information/intravaginal-clindamycin/","result":{"pageContext":{"chapter":{"id":"ecf84ab7-5f32-5135-a8c2-b302e217480a","slug":"intravaginal-clindamycin","fullItemName":"Intravaginal clindamycin","depth":2,"htmlHeader":"<!-- begin field 8bbae607-8dbf-4122-b8bb-e1f4e1592f37 --><h2>What do I need to know about prescribing intravaginal clindamycin?</h2><!-- end field 8bbae607-8dbf-4122-b8bb-e1f4e1592f37 -->","summary":"","htmlStringContent":"<!-- begin item d2ee1deb-d497-4ca7-abd8-2450290b09d7 --><!-- begin field 1dd21fd4-f7a8-442d-9451-9ac98715df5a --><ul><li><strong>Do not prescribe intravaginal clindamycin cream to:</strong><ul><li>Women previously found to be hypersensitive to preparations containing clindamycin or to any of the excipients.</li><li>Women who have demonstrated lincomycin sensitivity, although cross-sensitization to lincomycin has not been demonstrated.</li><li>Women with a history of inflammatory bowel disease or a history of antibiotic-associated colitis.</li></ul></li><li><strong>Prescribe i</strong><strong><strong>ntrav</strong>aginal </strong><strong>clindamycin cream</strong><strong> with caution in:</strong><ul><li>Pregnant women — the manufacturer recommends that clindamycin should be used in pregnancy only if clearly needed.<ul><li>There are no adequate and well-controlled studies in pregnant women during their first trimester. However, there was evidence of maternal toxicity and embryofoetal toxicity in animal studies.</li></ul></li><li>Breastfeeding women — the manufacturer recommends that a full assessment of benefit and risk should be made when considering using intravaginal clindamycin in a nursing mother.<ul><li>It is not known if clindamycin is excreted in breast milk following vaginal administration. However, oral and parenteral clindamycin have been reported to appear in breast milk.</li></ul></li></ul></li><li><strong>Intravaginal clindamycin can be absorbed in sufficient amounts to produce systemic effects. </strong><ul><li>Pseudomembranous colitis can occur with most antibiotics, but it appears to be more common with clindamycin [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">BNF 75, 2018</a>]. The risk is likely to be much less with intravaginal clindamycin (than oral clindamycin) because only a small amount of drug is absorbed. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a> for more information on pseudomembranous colitis.</li><li>Other possible adverse effects of intravaginal clindamycin cream include:<ul><li>Common — cervicitis (very common); vaginal candidiasis, vulvovaginitis; abdominal cramps; pruritus (non-application site); vulvovaginal disorder, vulvovaginal discomfort, and vaginal discharge.</li><li>Uncommon — vaginitis/vaginal infection, urinary tract infection, candidiasis (body), fungal infection; allergic reaction; taste disturbance; headache and dizziness; vertigo; epistaxis; abdominal pain, halitosis, diarrhoea, nausea, vomiting, constipation, dyspepsia, flatulence; rash, erythema, urticaria; dysuria, glycosuria, proteinuria; vaginal pain.</li><li>Unknown frequency — trichomonal vaginitis, bacterial infection, upper respiratory infection, candidiasis (skin); hyperthyroidism; generalized abdominal pain, localized abdominal pain, abdominal distension; maculopapular rash; back pain; menstrual disorder, metrorrhagia, endometriosis, pelvic pain; abnormal labour; inflammatory swelling, generalized pain; abnormal microbiological test.</li></ul></li></ul></li><li><strong>Advise the woman that:</strong><ul><li>If diarrhoea develops, she should discontinue treatment immediately and seek medical advice.</li><li>She should not rely on barrier methods of contraception during treatment with intravaginal clindamycin cream, or for 5 days after treatment.<ul><li>Clindamycin intravaginal cream contains oil-based components, some of which have been shown to weaken the rubber of condoms and diaphragms, making them less effective as barrier methods of contraception or as protection from sexually transmitted infection.</li></ul></li></ul></li><li><strong>Possible drug interactions of intravaginal clindamycin cream include:</strong><ul><li>Erythromycin — cross resistance has been demonstrated between erythromycin and clindamycin. Antagonism has been demonstrated between clindamycin and erythromycin in vitro.</li><li>Vitamin K antagonists (for example warfarin) — there have been reports of raised international normalized ratio (INR) tests and increased bleeding with the combined use of vitamin K antagonists and clindamycin (including topical preparations).<ul><li>INR tests should be more frequently monitored if these medicines are used concomitantly.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">ABPI, 2018</a>]</p><!-- end field 1dd21fd4-f7a8-442d-9451-9ac98715df5a --><!-- end item d2ee1deb-d497-4ca7-abd8-2450290b09d7 -->","topic":{"id":"865cdea2-9043-57ef-8b25-031205cdd37d","topicId":"afc41d7e-87dd-41b7-bbc7-b86b9168703c","topicName":"Bacterial vaginosis","slug":"bacterial-vaginosis","lastRevised":"Last revised in October 2018","chapters":[{"id":"f7fe1c4f-d424-53b7-9e1d-2e724534b550","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"ff6b3e14-7f5b-50db-8eee-ad227bf399c7","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"9d2f35ec-215f-5ee1-b407-2c5b68e931b0","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"06809c66-f539-5454-a18a-ff951a80494b","slug":"changes","fullItemName":"Changes"},{"id":"0872ed37-dd2a-58ae-ba58-ecd7dd9c964e","slug":"update","fullItemName":"Update"}]},{"id":"b96f10d4-f421-527a-bcaf-8e5e46afb0b5","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"7b27492c-f7b2-5bdf-8be5-596f1ad99050","slug":"goals","fullItemName":"Goals"},{"id":"8b94b860-815d-522b-b4fe-461ef978443a","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"b1dc3d72-ac27-5757-be13-e2015daa0798","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"8cef0513-bbd8-5919-961e-a28c7cfdd421","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"7bc7f747-27e8-5daa-9d10-380bdcd0f2e2","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"e58af854-9d1b-51ce-a49a-83df8540a21a","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d6cf6c66-7d92-5d41-933f-a9a879fa36d4","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ebdd3d77-69b1-523d-a4ac-4de1bd53fcfe","slug":"definition","fullItemName":"Definition"},{"id":"7f17b28f-8990-5777-98b2-0b0a488d883f","slug":"contributing-factors","fullItemName":"Contributing factors"},{"id":"276cab7f-4264-59d9-8986-e8de8d64e45e","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9a592036-9b11-587b-8576-77aac8d2b2ef","slug":"complications","fullItemName":"Complications"}]},{"id":"a011fb71-c488-53bd-b5ca-10e92c77583a","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"b250f8fd-847f-5844-a2d6-32014c81a438","slug":"assessment","fullItemName":"Assessment"},{"id":"e655909b-34b2-55ce-8897-68a2131e1a0c","slug":"examination-investigations","fullItemName":"Examination and investigations"},{"id":"5cc72fff-2222-558d-815e-907a5a25c2ef","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"0ae8498b-179a-5f9f-8ece-c5004a1ed196","fullItemName":"Management","slug":"management","subChapters":[{"id":"c43aecb1-cb55-5433-a0ce-81481bc43060","slug":"women-who-are-not-pregnant","fullItemName":"Scenario: Women who are not pregnant"},{"id":"e17bea46-46ca-5a5a-8f23-6d2541ef18b2","slug":"women-who-are-pregnant","fullItemName":"Scenario: Women who are pregnant"}]},{"id":"ff8ddbda-8b29-5d43-ad60-5aeb14b120d3","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"39735e82-4c9f-5aa2-97c7-1496f80b7c1f","slug":"oral-metronidazole","fullItemName":"Oral metronidazole"},{"id":"5eef68f3-35a3-5708-a789-014713e8af64","slug":"intravaginal-metronidazole","fullItemName":"Intravaginal metronidazole"},{"id":"ecf84ab7-5f32-5135-a8c2-b302e217480a","slug":"intravaginal-clindamycin","fullItemName":"Intravaginal clindamycin"}]},{"id":"dbca4e81-4cb5-5161-95af-5aed06ab1909","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"bab503ee-9268-578a-957b-b6f29998ba50","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a1542e98-52d3-5650-8f50-017cdafb6bb1","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"dddaaa3b-0dea-5b97-a24a-18f6f861a9b4","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"305419c2-e2ba-51d7-b38f-9d98fdb980ed","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"b64a9957-d6e0-5d40-9465-e092bfde8548","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"748d8b76-5aee-5fe6-898a-43bbffd5751b","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"efc1492f-d327-53ae-b257-f0f17e740c27","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"ff8ddbda-8b29-5d43-ad60-5aeb14b120d3","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}